A Phase II Study of the Farnesyltransferase Inhibitor ZARNESTRA (Tipifarnib, R115777, NSC #702818, IND #58,359) in Complete Remission Following Induction and/or Consolidation Chemotherapy in Adults With Poor-Risk Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplasia (MDS).
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2013
At a glance
- Drugs Tipifarnib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 02 Nov 2007 Status change from in progress to completed.
- 05 Sep 2005 New trial record.